Quarterly Report Q1 2017

April 16, 2018

Prometic reports 2017 first quarter highlights and financial results

  •  $69.3 million in new 2017 cash inflows from transactions negotiated in Q1

o $21.1 million from warrants exercise received in Q1
o $25.0 million from the Structured Alpha financing received in Q2
o $23.2 million cash to follow in 2017 from the SRAM China transaction

 

  •  PBI-4050s’ clinical efficacy confirmed in completed IPF open label phase 2 clinical trial - PBI-4050 advancing into placebo controlled phase 2/3 clinical trials for IPF and CKD
  • Rolling submission of the plasminogen BLA with the U.S. FDA completed
Previous Flipbook
Quarterly Report Q2 2017
Quarterly Report Q2 2017

Prometic reports 2017 second quarter highlights and financial results

No More Flipbooks